# US 2016/0355506 A1 · Crystalline salt form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0355506 A1
- Document ID: US20160355506A1
- Status: Published application
- Kind: A1
- Application number: 15/101,832
- Filed: 2014-12-02
- Published: 2016-12-08
- Earliest claimed: 2013-12-03
- Assignees: Actelion Pharmaceuticals Ltd.
- Applicants: Actelion Pharmaceuticals Ltd
- Inventors: Christoph BOSS; Christine BROTSCHI; Markus GUDE; Bibia HEIDMANN; Thierry SIFFERLEN; Markus VON RAUMER; Jodi T. WILLIAMS
- Web page: https://patentgrep.com/patent/US20160355506A1

## CPC

- C07D 403/14: containing three or more hetero rings
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/22: Anxiolytics
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The invention relates to a crystalline form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone hydrochloride, processes for the preparation thereof, pharmaceutical compositions containing said crystalline form, and its use as medicament, especially as orexin receptor antagonist.

## Claims

### Claim 1

A crystalline form of the compound (S)-(2-(6-chloro-7-methyl-1H-benzo [d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone; wherein said compound is present in form of the hydrochloric acid salt; wherein said crystalline salt form comprises peaks in the X-ray powder diffraction diagram at the following angles of refraction 2θ: 11.0°, 24.1° and 24.5°, wherein said X-ray powder diffraction diagram is obtained by using combined Cu Kα1 and Kα2 radiation, without Kα2 stripping; and the accuracy of the 2θ values is in the range of 2θ+/−0.2°.

### Claim 2 (depends on 1)

A crystalline form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone hydrochloride according to claim 1, comprising peaks in the X-ray powder diffraction diagram at the following angles of refraction 2θ: 9.2°, 11.0°, 13.8°, 15.1°, 16.3°, 16.8°, 19.8°, 24.1°, 24.5°, and 27.3°, wherein said X-ray powder diffraction diagram is obtained by using combined Cu Kα1 and Kα2 radiation, without Kα2 stripping; and the accuracy of the 2θ values is in the range of 2θ+/−0.2°.

### Claim 3 (depends on 1)

A crystalline form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone hydrochloride according to claim 1, which essentially shows the X-ray powder diffraction pattern as depicted in FIG. 2.

### Claim 4 (depends on 1)

A pharmaceutical composition comprising the crystalline form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone hydrochloride according to claim 1, and a pharmaceutically acceptable carrier.

### Claim 5

(canceled)

### Claim 6

(canceled)

### Claim 7

(canceled)

### Claim 8

(canceled)

### Claim 9

(canceled)

### Claim 10 (depends on 1)

A method of treatment or prophylaxis of sleep disorders, anxiety disorders, addiction disorders, cognitive dysfunctions, mood disorders, or appetite disorders; comprising administering to a patient an effective amount of the crystalline form of (S)-(2-(6-chloro-7-methyl-1H-benzo [d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone hydrochloride according to claim 1.

### Claim 11 (depends on 10)

The method of claim 10, wherein the sleep disorders are selected from the group consisting of dyssomnias, parasomnias, sleep disorders associated with a general medical condition and substance-induced sleep disorders.

### Claim 12 (depends on 1)

A method of treatment or prevention of a mental health disease or disorder relating to orexinergic dysfunctions; comprising administering to a patient an effective amount of the crystalline form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone hydrochloride according to claim 1.

### Claim 13 (depends on 4)

A method of treatment or prevention of a mental health disease or disorder relating to orexinergic dysfunctions; comprising administering to a patient an effective amount of the pharmaceutical composition according to claim 4.
